The MHRA mandates that all nicotine vape products must be notified and reviewed before being allowed on the UK market, and encourages reporting of any adverse reactions via its Yellow Card Scheme. These measures aim to protect consumers and maintain strict safety standards for vape products.
Table of Contents
MHRA and Vape Regulation: Regulatory Authority and Oversight
In the UK, the Medicines and Healthcare products Regulatory Agency (MHRA) is the official authority overseeing nicotine-containing e-cigarettes and related products. Under the Tobacco and Related Products Regulations 2016 (TRPR), amended in 2020, the MHRA manages a compulsory notification system for all nicotine-containing e-cigarettes and refillable liquids before they can legally be sold in Great Britain and Northern Ireland.
However, remember that MHRA does not control or regulate legal THC vape pens sold as wellness products. Instead, the regulation of THC vapes falls under the Misuse of Drugs Act (MDA) 1971 and related drug laws, not under MHRA or consumer nicotine regulations.
What the MHRA Says About THC Vape Safety and Product Monitoring
The MHRA emphasises that public safety remains its top priority. The agency has highlighted that numerous suspected adverse reactions involving nicotine e-cigarettes and e-liquids had been reported via its Yellow Card Scheme a system used to track product safety issues. Reports included complaints of respiratory symptoms, irritation, or device malfunction.
Although these reports are not related to weed pens that are relatively safer, some of the side effects of these vapes might be similar to those of nicotine vapes, particularly in individuals sensitive to vaping.
Healthcare professionals and consumers are encouraged to report any unexpected side effects or suspected product safety issues. The MHRA uses this data to monitor trends and ensure that only safe products remain on the market.
Recent Clarifications and Updates from MHRA
In 2025, the MHRA updated its Guidance Hub for e-cigarette and vape products, confirming its role in implementing TRPR changes and detailing notification procedures for manufacturers and importers. This includes a requirement that all products cartridges, disposables, liquids fall within specified safety and quality standards.
Manufacturers are required to notify via separate systems for Great Britain and Northern Ireland from January 2021 onwards, with associated fees. Retailers not being the notification party must still confirm that each product they sell is on the MHRA register.
Ingredient Bans, Labelling Rules, and Consumer Transparency
MHRA-administered regulations strictly prohibit certain ingredients such as diacetyl, vitamin E acetate, caffeine, and taurine in vape products. These ingredients have been identified internationally as potential health hazards, particularly when inhaled.
Additionally, products must also meet stringent packaging regulations: child-resistant closures, tamper-evident seals, accurate nicotine strength labelling (maximum 20 mg/ml), and no medical or smoking‑cessation claims. MHRA strictly prohibits making false claims during the marketing of the products.
Hazard Reporting via Yellow Card: Why It Matters
The Yellow Card Scheme allows both healthcare professionals and members of the public to report suspected adverse events related to vape products. Users are encouraged to provide details such as brand, batch number, flavour, user experience, and timing of symptoms.
This voluntary reporting supports proactive safety surveillance. Manufacturers selling notified products remain under MHRA oversight, and ongoing reports may trigger additional investigations or market reviews if safety concerns arise.
What Consumers Should Do
If you’re purchasing a legal THC vape (i.e. one containing less than 1 mg THC per container), it should be sold only by a supplier that:
- Clearly states the total THC content, with certification confirming it remains under the legal threshold.
- Provides batch-specific lab reports showing cannabinoid and terpene content, proving product purity and compliance.
- Discloses all ingredients transparently, with no medical or therapeutic claims, since unlicensed products cannot legally be marketed as treatments.
Because THC vapes are regulated via drug legislation—not via the MHRA or nicotine regulations—the Yellow Card adverse reaction reporting system does not typically apply. Instead, any health incidents should be shared with Trading Standards or local public health bodies, who oversee substance safety and enforce drug laws.
Avoid vapes sold via marketplaces, social media adverts, market stalls, or overseas websites especially those claiming “high THC” or fast, strong effects. These are usually unregulated, may contain synthetic cannabinoids or harmful additives, and pose legal and health risks.
Concluding Summary
The MHRA’s vape safety framework relies on strict product notification, ingredient regulation, side-effect reporting, and transparent oversight of the vape market. These regulatory measures help ensure that only high-quality, verified e-cigarette products reach UK consumers and that any safety concerns are rapidly flagged and addressed.
Of course, most of these recommendations are for nicotine vapes, but they do have some indirect implications for CBD and THC vapes, too. For example, MHRA monitoring helped understand that adding certain additives, such as vitamin E, if added to various vapes, can cause severe side effects, thus helping improve the safety of CBD and THC vapes, too.